Related Experiment Video
Updated: Jun 9, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Definitive proton therapy for unresectable trunk soft tissue sarcoma: a single-institution prospective registry-based
Shuou Sudo1,2, Koichiro Nakajima1, Hiroyuki Ogino1
1Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Clinical and Translational Radiation Oncology
|June 8, 2026
Summary
Proton therapy (PT) is a safe and effective treatment for unresectable trunk soft tissue sarcomas (STS), maintaining quality of life. This study suggests PT should be considered in multidisciplinary treatment strategies for STS.
Area of Science:
- Radiation Oncology
- Medical Physics
- Oncology
Background:
- Optimal management for unresectable trunk soft tissue sarcomas (STS) is not well-established.
- The role of radiotherapy in treating unresectable trunk STS requires further clarification.
Purpose of the Study:
- To evaluate clinical outcomes and quality of life (QOL) in patients with unresectable trunk STS treated with definitive proton therapy (PT).
Main Methods:
- Retrospective single-institution review of patients with unresectable trunk STS treated with definitive PT.
- Endpoints included overall survival (OS), local control (LC), progression-free survival (PFS), toxicity, and QOL.
Main Results:
- Three-year OS, LC, and PFS rates were 51%, 81%, and 39%, respectively.
- No grade ≥3 toxicities were observed, and QOL was generally maintained.
- Gross tumor volume ≥300 cm³ was associated with worse OS.
Conclusions:
- Proton therapy (PT) is a safe and effective treatment option for unresectable trunk STS.
- PT's favorable safety profile and dosimetric advantages make it suitable for multidisciplinary treatment strategies.
- PT should be actively considered for patients with unresectable trunk STS.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...